Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.56 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.56 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228463 | 0.92 | HPGD (0.63) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL4696278 | 0.91 | ALDH1A1 (0.68) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL28468465 | 0.91 | ALDH1A1 (0.61) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL20138341 | 0.89 | ALDH1A1 (0.72) | HPGDALDH1A1TSHRCNR1LMNA | |
| SCHEMBL12075919 | 0.86 | HPGD (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25243252 | 0.86 | TSHR (0.47) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL1199411 | 0.86 | HTT (0.53) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL1299556 | 0.82 | HPGD (0.68) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2956853 | 0.82 | — | — | |
| SCHEMBL19569940 | 0.82 | ALDH1A1 (0.75) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112955215-B | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2024-05-17 | — | — | CN | claimed |
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | claimed |
| EP-3873600-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | claimed |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-25 | — | — | US | claimed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | claimed |
| EP-3873600-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2021-09-08 | — | — | EP | claimed |
| CN-112955215-A | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | claimed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | claimed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | claimed |
| EP-3590933-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2021-01-06 | — | — | EP | claimed |
| WO-2008021375-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-21 | — | — | WO | claimed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | claimed |
| WO-2008005295-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-10 | — | — | WO | claimed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | claimed |
| JP-2007501264-A | — | — | 2007-01-25 | — | — | JP | claimed |
| WO-2006137658-A1 | NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONGBU HITEK CO., LTD. (KR) | 2006-12-28 | — | — | WO | claimed |
| EP-1633748-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | claimed |
| EP-1495020-A1 | N-(MORPHOLIN-2YL) METHYL ACETAMIDE DERIVATIVES AS CCR-3 ANTAGONISTS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-01-12 | — | — | EP | claimed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | claimed |
| WO-2003082863-A1 | N-(MORPHOLIN-2YL) METHYL ACETAMIDE DERIVATIVES AS CCR-3 ANTAGONISTS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | HPGD 598/4885CHRNB2 3287/4885CHRNA3 2612/4885 |
| US-20080033002-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | HPGD 1197/4885CHRNB2 16/4885CHRNA3 12/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | HPGD 3465/4885CHRNB2 1705/4885CHRNA3 2138/4885 |
| US-10973817-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | HPGD 3465/4885CHRNB2 1705/4885CHRNA3 2138/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | HPGD 381/4885CHRNB2 1089/4885CHRNA3 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.